KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Bristol Myers Squibb (BMY) Receivables - Net (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Receivables - Net for 17 consecutive years, with $11.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 6.21% to $11.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $11.4 billion, a 6.21% increase, with the full-year FY2025 number at $11.4 billion, up 6.21% from a year prior.
  • Receivables - Net was $11.4 billion for Q4 2025 at Bristol Myers Squibb, roughly flat from $11.4 billion in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $11.4 billion in Q3 2025 to a low of $7.8 billion in Q1 2021.
  • A 5-year average of $9.7 billion and a median of $9.8 billion in 2022 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: dropped 13.24% in 2022, then skyrocketed 33.02% in 2024.
  • Bristol Myers Squibb's Receivables - Net stood at $9.4 billion in 2021, then grew by 5.52% to $9.9 billion in 2022, then grew by 10.47% to $10.9 billion in 2023, then dropped by 1.59% to $10.7 billion in 2024, then grew by 6.21% to $11.4 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Receivables - Net are $11.4 billion (Q4 2025), $11.4 billion (Q3 2025), and $11.4 billion (Q2 2025).